Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 9 Jan 2021]

Accessing the syndemic of COVID-19 and malaria intervention in Africa
The pandemic of the coronavirus disease 2019 (COVID-19) has caused substantial disruptions to health services in the low and middle-income countries with a high burden of other diseases, such as malaria in sub…
Authors: Benyun Shi, Jinxin Zheng, Shang Xia, Shan Lin, Xinyi Wang, Yang Liu, Xiao-Nong Zhou and Jiming Liu
Citation: Infectious Diseases of Poverty 2021 10:5
Content type: Research Article
Published on: 7 January 2021

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 9 Jan 2021]

Efforts to mitigate the economic impact of the COVID-19 pandemic: potential entry points for neglected tropical diseases
The damage inflicted by the coronavirus diseases 2019 (COVID-19) pandemic upon humanity is and will continue to be considerable. Unprecedented progress made in global health over the past 20 years has reverted…
Authors: John P. Ehrenberg, Jürg Utzinger, Gilberto Fontes, Eliana Maria Mauricio da Rocha, Nieves Ehrenberg, Xiao-Nong Zhou and Peter Steinmann
Citation: Infectious Diseases of Poverty 2021 10:2
Content type: Scoping Review
Published on: 4 January 2021

International Journal of Infectious Diseases
January 2021 Volume 102 p1-590
https://www.ijidonline.com/current

Coronavirus (COVID-19) Collection
Healthcare worker infections and deaths due to COVID-19: A survey from 37 nations and a call for WHO to post national data on their website
Hakan Erdem, Daniel R. Lucey
Published online: October 29, 2020

JAMA
January 5, 2021, Vol 325, No. 1, Pages 9-96
https://jamanetwork.com/journals/jama/currentissue

Original Investigation
Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular DiseaseA Randomized Clinical Trial
Orly Vardeny, PharmD, MS; KyungMann Kim, PhD; Jacob A. Udell, MD, MPH; et al.
JAMA. 2021;325(1):39-49. doi:10.1001/jama.2020.23649
This randomized clinical trial compares the effect of high-dose vs standard-dose influenza vaccine on all-cause mortality and hospitalizations due to cardiovascular or pulmonary causes in patients with high-risk cardiovascular disease.

JAMA
January 5, 2021, Vol 325, No. 1, Pages 9-96
https://jamanetwork.com/journals/jama/currentissue

Editorial
Influenza Vaccine for Patients With High-risk Cardiovascular Disease
Manish M. Patel, MD, MS; Timothy M. Uyeki, MD, MPH, MPP

JAMA
January 5, 2021, Vol 325, No. 1, Pages 9-96
https://jamanetwork.com/journals/jama/currentissue

Viewpoint
How to Leverage the Medicare Program for a COVID-19 Vaccination Campaign
Nicole Lurie, MD, MSPH; Bettina Experton, MD, MPH
free access has active quiz
JAMA. 2021;325(1):21-22. doi:10.1001/jama.2020.22720
This Viewpoint proposes that Medicare claims data could inform the rollout of a COVID-19 vaccination program in the US, including notifying beneficiaries of their risk and prioritization and supporting efforts to allocate the vaccine and monitor its uptake, immunogenicity, and safety.

JAMA Network
COVID-19 Update January 9, 2021

These articles on COVID-19 were published across the JAMA Network in the last week.
Selected Articles
Opinion
Problems With Paying People to Be Vaccinated Against COVID-19
Emily A. Largent, JD, PhD, RN; Franklin G. Miller, PhD

Journal of Community Health
Volume 46, issue 1, February 2021
https://link.springer.com/journal/10900/volumes-and-issues/46-1

Articles
Young Adult Human Papillomavirus and Influenza Vaccine Coverage: A Comparison Across College Enrollment Status
Authors: Kara Mathewson, Maria Sundaram, Robert A. Bednarczyk,
Content type: Original Paper
Published: 15 May 2020
Pages: 13 – 21

Journal of Infectious Diseases
Volume 223, Issue 1, 1 January 2021
https://academic.oup.com/jid/issue/223/1

EDITORIAL COMMENTARIES
The Long and Winding Road to Eradicate Vaccine-Related Polioviruses
Stephen L Cochi, Mark A Pallansch
The Journal of Infectious Diseases, Volume 223, Issue 1, 1 January 2021, Pages 7–9, https://doi.org/10.1093/infdis/jiaa393

Journal of Infectious Diseases
Volume 223, Issue 1, 1 January 2021
https://academic.oup.com/jid/issue/223/1

VIRUSES
Implication of a High Risk for Type 2 Vaccine-Derived Poliovirus Emergence and Transmission After the Switch From Trivalent to Bivalent Oral Poliovirus Vaccine
Dongmei Yan, Dongyan Wang, Yong Zhang, Xiaolei Li, Haishu Tang …
The Journal of Infectious Diseases, Volume 223, Issue 1, 1 January 2021, Pages 113–118, https://doi.org/10.1093/infdis/jiaa386
The switch from trivalent to bivalent oral poliovirus vaccine can provide high-level immunity against type 1 and 3 poliovirus but not against type 2, indicating a high risk of type 2 vaccine-derived poliovirus emergence and transmission.

Journal of Infectious Diseases
Volume 223, Issue 1, 1 January 2021
https://academic.oup.com/jid/issue/223/1

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
Ananda S Bandyopadhyay, Chris Gast, Elizabeth B Brickley, Ricardo Rüttimann, Ralf Clemens …
The Journal of Infectious Diseases, Volume 223, Issue 1, 1 January 2021, Pages 119–127, https://doi.org/10.1093/infdis/jiaa390

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 9 Jan 2021]

Ten recommendations to improve pharmacy practice in low and middle-income countries (LMICs)
Medicines are important health interventions and their appropriate use could improve health outcomes. Throughout the globe, pharmacists play a very important role to improve the use of medicines. Though high-i…
Authors: Zaheer-Ud-Din Babar
Citation: Journal of Pharmaceutical Policy and Practice 2021 14:6
Content type: Commentary
Published on: 6 January 2021

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 9 Jan 2021]

Exploring healthcare professionals’ knowledge, attitude, and practices towards pharmacovigilance: a cross-sectional survey
Spontaneous reporting of adverse drug reactions (ADRs) is a method of monitoring the safety of drugs and is the basic strategy for the post-marketing surveillance of the suspected drugs. Despite its importance…
Authors: Rabia Hussain, Mohamed Azmi Hassali, Furqan Hashmi and Tayyaba Akram
Citation: Journal of Pharmaceutical Policy and Practice 2021 14:5
Content type: Research
Published on: 4 January 2021

Journal of Travel Medicine
Volume 28, Issue 1, January 2021
https://academic.oup.com/jtm/issue

Perspectives
Neglected tropical diseases in non-endemic countries in the era of COVID-19 pandemic: the great forgotten
Marta Tilli, MD, Piero Olliaro, PhD, Federico Gobbi, PhD, Zeno Bisoffi, PhD, Alessandro Bartoloni, MD …
Journal of Travel Medicine, Volume 28, Issue 1, January 2021, taaa179, https://doi.org/10.1093/jtm/taaa179
In non-endemic countries, the access to healthcare for migrants and other patients with NTDs may be hampered by new barriers linked to the COVID-19 pandemic. Low awareness of health care professionals on the opportunistic potential of some NTDs may lead to unfavorable outcome of COVID-19 patients treated with immunomodulatory drugs.

Journal of Travel Medicine
Volume 28, Issue 1, January 2021
https://academic.oup.com/jtm/issue

Editor’s Choice
Cholera in travellers: improving vaccination guidance in Europe
Rogelio López-Vélez, MD, PhD, DTM&H, Danilo Presotto, PhD
Journal of Travel Medicine, Volume 28, Issue 1, January 2021, taaa209, https://doi.org/10.1093/jtm/taaa209

The Lancet
Jan 09, 2021 Volume 397 Number 10269 p71-170
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Climate and COVID-19: converging crises
The Lancet

The Lancet
Jan 09, 2021 Volume 397 Number 10269 p71-170
https://www.thelancet.com/journals/lancet/issue/current

Comment
Oxford–AstraZeneca COVID-19 vaccine efficacy
Maria Deloria Knoll, Chizoba Wonodi

The Lancet
Jan 09, 2021 Volume 397 Number 10269 p71-170
https://www.thelancet.com/journals/lancet/issue/current

Public health role for fractional dosage of yellow fever vaccine
J Erin Staples, Alba-Maria Ropero Alvarez

The Lancet
Jan 09, 2021 Volume 397 Number 10269 p71-170
https://www.thelancet.com/journals/lancet/issue/current

Articles
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey, et al. on behalf of the Oxford COVID Vaccine Trial Group
Open Access
A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.

The Lancet
Jan 09, 2021 Volume 397 Number 10269 p71-170
https://www.thelancet.com/journals/lancet/issue/current

Review
The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises
Nick Watts, et al
Executive summary
The Lancet Countdown is an international collaboration established to provide an independent, global monitoring system dedicated to tracking the emerging health profile of the changing climate.
The 2020 report presents 43 indicators across five sections: climate change impacts, exposures, and vulnerabilities; adaptation, planning, and resilience for health; mitigation actions and health co-benefits; economics and finance; and public and political engagement. This report represents the findings and consensus of the 35 leading academic institutions and UN agencies that make up The Lancet Countdown, and draws on the expertise of climate scientists, geographers, engineers, experts in energy, food, and transport, economists, social, and political scientists, data scientists, public health professionals, and doctors.

The Lancet
Jan 09, 2021 Volume 397 Number 10269 p71-170
https://www.thelancet.com/journals/lancet/issue/current

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial
Aitana Juan-Giner, et al
Stocks of yellow fever vaccine are insufficient to cover exceptional demands for outbreak response. Fractional dosing has shown efficacy, but evidence is limited to the 17DD substrain vaccine. We assessed the immunogenicity and safety of one-fifth fractional dose compared with standard dose of four WHO-prequalified yellow fever vaccines produced from three substrains.

Nature Genetics
Volume 53 Issue 1, January 2021
https://www.nature.com/ng/volumes/53/issues/1

Comment | 07 January 2021
Toward better governance of human genomic data
Here, we argue that, in line with the dramatic increase in the collection, storage and curation of human genomic data for biomedical research, genomic data repositories and consortia have adopted governance frameworks to both enable wide access and protect against possible harms. However, the merits and limitations of different governance frameworks in achieving these twin aims are a matter of ongoing debate in the scientific community; indeed, best practices and points for consideration are notably absent in devising governance frameworks for genomic databases. According to our collective experience in devising and assessing governance frameworks, we identify five key functions of ‘good governance’ (or ‘better governance’) and three areas in which trade-offs should be considered when specifying policies within those functions. We apply these functions as a benchmark to describe, as an example, the governance frameworks of six large-scale international genomic projects.
Kieran C. O’Doherty, Mahsa Shabani[…] & Wylie Burke

Nature Reviews Drug Discovery
Volume 20 Issue 1, January 2021
https://www.nature.com/nrd/volumes/20/issues/1

Comment | 23 October 2020
Improving data sharing to increase the efficiency of antibiotic R&D
Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, such as the recent joint data contribution from Merck and Kyorin to the Pew Charitable Trusts’ SPARK platform, has a key role.
Wes Kim, Kevin Krause[…] & Kevin Outterson

An Audience With | 11 December 2020
Emer Cooke
With multiple COVID-19 vaccines approaching the finish line, and dozens of COVID-19 drugs in development, more eyes are on the European Medicines Agency (EMA)’s decisions than ever before. Emer Cooke, who started as Executive Director of the EMA in November, is ready. Cooke, a pharmacist by training, has more than 30 years’ experience in pharmaceutical regulation. During this time, she has seen the system transform: the typewriters and carbon copy are gone, replaced by unprecedented volumes of data and complexity. With prior roles that have included oversight of the regulation of medical products at the World Health Organization, Head of Inspections at the EMA and Head of International Affairs at the EMA, she is prepared for the multidisciplinary nature of the challenges ahead. She spoke with Asher Mullard about the speed of progress with COVID-19 vaccines, the potential longer-term impacts of the pandemic on regulatory affairs and her goals for the EMA once the world returns to business as usual.
Asher Mullard

Nature Reviews Drug Discovery
Volume 20 Issue 1, January 2021
https://www.nature.com/nrd/volumes/20/issues/1

An Audience With | 11 December 2020
Emer Cooke
With multiple COVID-19 vaccines approaching the finish line, and dozens of COVID-19 drugs in development, more eyes are on the European Medicines Agency (EMA)’s decisions than ever before. Emer Cooke, who started as Executive Director of the EMA in November, is ready. Cooke, a pharmacist by training, has more than 30 years’ experience in pharmaceutical regulation. During this time, she has seen the system transform: the typewriters and carbon copy are gone, replaced by unprecedented volumes of data and complexity. With prior roles that have included oversight of the regulation of medical products at the World Health Organization, Head of Inspections at the EMA and Head of International Affairs at the EMA, she is prepared for the multidisciplinary nature of the challenges ahead. She spoke with Asher Mullard about the speed of progress with COVID-19 vaccines, the potential longer-term impacts of the pandemic on regulatory affairs and her goals for the EMA once the world returns to business as usual.
Asher Mullard

Nature Reviews Drug Discovery
Volume 20 Issue 1, January 2021
https://www.nature.com/nrd/volumes/20/issues/1

Perspective | 16 November 2020
Improving target assessment in biomedical research: the GOT-IT recommendations
Academic research has a key role in identifying new drug targets, but to lead to new drugs this research must progress to testing drug candidates in clinical trials, which are typically conducted by industry. This Perspective presents a framework to support academic scientists and funders in prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical trials.
Christoph H. Emmerich, Lorena Martinez Gamboa[…] & Michael J. Parnham

New England Journal of Medicine
January 7, 2021 Vol. 384 No. 1
http://www.nejm.org/toc/nejm/medical-journal

Editorials
Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout
In this audio interview conducted on January 6, 2021, the editors are joined by cardiologist and primary care physician Thomas H. Lee to discuss how health care organizations are planning vaccine rollout and uptake both among their staffs and in their communities.

New England Journal of Medicine
January 7, 2021 Vol. 384 No. 1
http://www.nejm.org/toc/nejm/medical-journal

Perspective
A Half-Century of Progress in Health: The National Academy of Medicine at 50: Human Molecular Genetics and Genomics — Important Advances and Exciting Possibilities
Francis S. Collins, M.D., Ph.D., Jennifer A. Doudna, Ph.D., Eric S. Lander, Ph.D., and Charles N. Rotimi, Ph.D.

PLoS One
http://www.plosone.org/
[Accessed 9 Jan 2021]

The development of nations conditions the disease space
Antonios Garas, Sophie Guthmuller, Athanasios Lapatinas
Research Article | published 07 Jan 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0244843
Using the economic complexity methodology on data for disease prevalence in 195 countries during the period of 1990-2016, we propose two new metrics for quantifying the disease space of countries. With these metrics, we analyze the geography of diseases and empirically investigate the effect of economic development on the health complexity of countries. We show that a higher income per capita increases the complexity of countries’ diseases. We also show that complex diseases tend to be non-ubiquitous diseases that are prevalent in disease-diversified (complex) countries, while non-complex diseases tend to be non-ubiquitous diseases that are prevalent in non-diversified (non-complex) countries. Furthermore, we build a disease-level index that links a disease to the average level of GDP per capita of the countries in which the disease is prevalent. With this index, we highlight the link between economic development and the complexity of diseases and illustrate how increases in income per capita are associated with more complex diseases.

PLoS One
http://www.plosone.org/
[Accessed 9 Jan 2021]

COVID-19 and the public response: Knowledge, attitude and practice of the public in mitigating the pandemic in Addis Ababa, Ethiopia
Zelalem Desalegn, Negussie Deyessa, Brhanu Teka, Welelta Shiferaw, Damen Hailemariam, Adamu Addissie, Abdulnasir Abagero, Mirgissa Kaba, Workeabeba Abebe, Berhanu Nega, Wondimu Ayele, Tewodros Haile, Yirgu Gebrehiwot, Wondwossen Amogne, Eva Johanna Kantelhardt, Tamrat Abebe
Research Article | published 07 Jan 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0244780

PLoS One
http://www.plosone.org/
[Accessed 9 Jan 2021]

The winding road to health: A systematic scoping review on the effect of geographical accessibility to health care on infectious diseases in low- and middle-income countries
Fleur Hierink, Emelda A. Okiro, Antoine Flahault, Nicolas Ray
Research Article | published 04 Jan 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0244921

PLoS One
http://www.plosone.org/
[Accessed 9 Jan 2021]

Consolidated Framework for Collaboration Research derived from a systematic review of theories, models, frameworks and principles for cross-sector collaboration
Larissa Calancie, Leah Frerichs, Melinda M. Davis, Eliana Sullivan, Ann Marie White, Dorothy Cilenti, Giselle Corbie-Smith, Kristen Hassmiller Lich
Research Article | published 04 Jan 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0244501
Cross-sector collaboration is needed to address root causes of persistent public health challenges. We conducted a systematic literature review to identify studies describing theories, models, frameworks and principles for cross-sector collaboration and synthesized collaboration constructs into the Consolidated Framework for Collaboration Research (CFCR). Ninety-five articles were included in the review. Constructs were abstracted from articles and grouped into seven domains within the framework: community context; group composition; structure and internal processes; group dynamics; social capital; activities that influence or take place within the collaboration; activities that influence or take place within the broader community; and activities that influence or take place both in the collaboration and in the community. Community engagement strategies employed by collaborations are discussed, as well as recommendations for using systems science methods for testing specific mechanisms of how constructs identified in the review influence one another. Researchers, funders, and collaboration members can use the consolidated framework to articulate components of collaboration and test mechanisms explaining how collaborations function. By working from a consolidated framework of collaboration terms and using systems science methods, researchers can advance evidence for the efficacy of cross-sector collaborations.

PNAS – Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/
[Accessed 9 Jan 2021]

Concerns for others increases the likelihood of vaccination against influenza and COVID-19 more in sparsely rather than densely populated areas
Haesung Jung and Dolores Albarracín
PNAS January 5, 2021 118 (1) e2007538118; https://doi.org/10.1073/pnas.2007538118

PNAS – Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/
[Accessed 9 Jan 2021]

Enforcement may crowd out voluntary support for COVID-19 policies, especially where trust in government is weak and in a liberal society
Katrin Schmelz
PNAS January 5, 2021 118 (1) e2016385118; https://doi.org/10.1073/pnas.2016385118

Science
08 January 2021 Vol 371, Issue 6525
http://www.sciencemag.org/current.dtl

Policy Forum
Coevolution of policy and science during the pandemic
By Yian Yin, Jian Gao, Benjamin F. Jones, Dashun Wang
Science08 Jan 2021 : 128-130 Full Access
Recent, high-quality science is being heard, but unevenly
Summary
Disconnects between science and policy, in which important scientific insights may be missed by policymakers and bad scientific advice may infect decision-making, are a long-standing concern (1–7). Yet, our systematic understanding of the use of science in policy remains limited (1, 4–6), partly because of the difficulty in reliably tracing the coevolution of policy and science at a large, global scale (3). Today, the world faces a common emergency in the COVID-19 pandemic, which presents a dynamic, uncertain, yet extraordinarily consequential policy environment across the globe. We combined two large-scale databases that capture policy and science and their interactions, allowing us to examine the coevolution of policy and science during the pandemic. Our analysis suggests that many policy documents in the COVID-19 pandemic substantially access recent, peer-reviewed, and high-impact science. And policy documents that cite science are especially highly cited within the policy domain. At the same time, there is a heterogeneity in the use of science across policy-making institutions. The tendency for policy documents to cite science appears mostly concentrated within intergovernmental organizations (IGOs), such as the World Health Organization (WHO), and much less so in national governments, which consume science largely indirectly through the IGOs. This close coevolution between policy and science offers a useful indication that a key link is operating, but it has not been a sufficient condition for effectiveness in containing the pandemic.

Vaccine
Volume 39, Issue 3 Pages 457-626 (15 January 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/3

Editorial Full text access
Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy
Michelle R. Holm, Gregory A. Poland

Vaccine
Volume 39, Issue 3 Pages 457-626 (15 January 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/3

Research article Abstract only
Preferences for a COVID-19 vaccine in Australia
Antonio Borriello, Daniel Master, Andrea Pellegrini, John M. Rose
Pages 473-479

Vaccine
Volume 39, Issue 3 Pages 457-626 (15 January 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/3

Discussion Full text access
BCG vaccine: Worrying proposal for COVID-19
Emanuel Sarinho, Ekaterini Goudouris, Dirceu Solé

Vaccine
Volume 39, Issue 3 Pages 457-626 (15 January 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/3

Research article Abstract only
“Does Pakistan still have polio cases?”: Exploring discussions on polio and polio vaccine in online news comments in Pakistan
Muhammad Ittefaq, Annalise Baines, Mauryne Abwao, Sayyed Fawad Ali Shah, Tayyab Ramzan
Pages 480-486

Vaccine
Volume 39, Issue 3 Pages 457-626 (15 January 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/3

Research article Open access
Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data
Clarisse Marchal, Manon Belhassen, Nicole Guiso, Flore Jacoud, … Mathieu Uhart
Pages 505-511

Vaccine
Volume 39, Issue 3 Pages 457-626 (15 January 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/3

Research article Abstract only
Physicians’ decision processes about the HPV vaccine: A qualitative study
Maité Bouchez, Jeremy K. Ward, Aurélie Bocquier, Daniel Benamouzig, … Pierre Verger
Pages 521-528

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 9 Jan 2021)

Open Access Article
Impact of Recommended Maternal Vaccination Programs on the Clinical Presentation of SARS-CoV-2 Infection: A Prospective Observational Study
by Maria Luisa de la Cruz Conty et al and on behalf of the Spanish Obstetric Emergency Group
Vaccines 2021, 9(1), 31; https://doi.org/10.3390/vaccines9010031 (registering DOI) – 08 Jan 2021
Abstract
The COVID-19 pandemic has raised questions about the possible cross immunity resulting from common vaccination programs and SARS-CoV-2 infection. Therefore, the Spanish Obstetric Emergency group performed a multicenter prospective study on the vaccination status of Influenza and Tdap (diphtheria, tetanus and pertussis vaccine […

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 9 Jan 2021)

Open Access Article
Vaccine Hesitancy on Social Media: Sentiment Analysis from June 2011 to April 2019
by Hilary Piedrahita-Valdés et al
Vaccines 2021, 9(1), 28; https://doi.org/10.3390/vaccines9010028 (registering DOI) – 07 Jan 2021
Abstract
Vaccine hesitancy was one of the ten major threats to global health in 2019, according to the World Health Organisation. Nowadays, social media has an important role in the spread of information, misinformation, and disinformation about vaccines. Monitoring vaccine-related conversations on social media […]

Value in Health
January 2021 Volume 24 Issue 1p1-144
https://www.valueinhealthjournal.com/current

THEMED SECTION: VACCINES
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
Florian Zeevat, Pascal Crépey, F. Christiaan K. Dolk, Arjan J. Postma, Vidya N.A. Breeveld-Dwarkasing,
Maarten J. Postma
Published online: December 18, 2020

Value in Health
January 2021 Volume 24 Issue 1p1-144
https://www.valueinhealthjournal.com/current

Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany
Stefan M. Scholz, Felix Weidemann, Oliver Damm, Bernhard Ultsch, Wolfgang Greiner, Ole Wichmann
Published online: November 04, 2020

Value in Health
January 2021 Volume 24 Issue 1p1-144
https://www.valueinhealthjournal.com/current

What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries
Allison Portnoy, Stephen C. Resch, Christian Suharlim, Logan Brenzel, Nicolas A. Menzies
Published online: November 02, 2020

Value in Health
January 2021 Volume 24 Issue 1p1-144
https://www.valueinhealthjournal.com/current

Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030
So Yoon Sim, Elizabeth Watts, Dagna Constenla, Shuoning Huang, Logan Brenzel, Bryan N. Patenaude
Published online: October 29, 2020

Value in Health
January 2021 Volume 24 Issue 1p1-144
https://www.valueinhealthjournal.com/current

Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches
Elizabeth Watts, So Yoon Sim, Dagna Constenla, Salin Sriudomporn, Logan Brenzel, Bryan Patenaude
Published online: October 17, 2020

Value in Health
January 2021 Volume 24 Issue 1p1-144
https://www.valueinhealthjournal.com/current

Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?
Josephine Mauskopf, Catherine Masaquel, Liping Huang
Published online: October 12, 2020

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 9 Jan 2021
Health
The Next Phase of Vaccination Will Be Even Harder
Getting vaccines to hospitals and nursing homes was supposed to be the easy part.
Sarah Zhang January 7, 2021
The vaccine rollout is not going as planned. Since mid-December, the U.S. has distributed 21.4 million doses of COVID-19 vaccines; fewer than one-third have actually made it into people’s arms. The problems have been many and varied: holiday delays, scheduling scams, long lines in some places, and not enough demand in others. These initial kinks are getting worked out, but that alone will not get us back to normal anytime soon. The next phase of the vaccine campaign—reaching tens of millions of elderly people and essential workers, along with the rest of the community—will be even harder…

BBC
http://www.bbc.co.uk/
Accessed 9 Jan 2021
Covid: India to begin vaccine rollout on 16 January
PM Narendra Modi hails a “landmark step” and says the aim is to vaccinate 300 million people by July.
Published 9 Jan 2021

The Economist
http://www.economist.com/
Accessed 9 Jan 2021
Vaccinating the world
The great task
The race to vaccinate the world against covid-19 has begun in earnest, posing problems for many and providing opportunities for some
Jan 9 Edition

Financial Times
https://www.ft.com/
Accessed 9 Jan 2021
Coronavirus treatment
Lex
Vaccine scepticism: needling doubts
Confidence in jabs will receive a boost if the Covid vaccine rollout goes well
January 9, 2021

Forbes
http://www.forbes.com/
Accessed 9 Jan 2021
9 Jan 2020
Russia’s Sputnik V COVID Vaccine: 1m Shots, Skepticism At Home, Politics Abroad
Russia’s campaign against COVID-19 is continuing, and has now passed the milestone of one million inoculations. As well as being an urgent matter of public health, this is also a matter of international prestige—and persuading a skeptical population.
By James Rodgers Senior Contributor

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 9 Jan 2021
[No new, unique, relevant content]

Foreign Policy
http://foreignpolicy.com/
Accessed 9 Jan 2021
Analysis
America’s Vaccine Diplomacy Is AWOL in the Middle East
China and Russia are spreading their vaccines—and forging new ties—to some of Washington’s closest allies.
Voice | Steven A. Cook January 8, 2021, 10:10 AM

The Guardian
http://www.guardiannews.com/
Accessed 9 Jan 2021
[No new, unique, relevant content]

New Yorker
http://www.newyorker.com/
Accessed 9 Jan 2021
A Reporter at Large
January 4 & 11, 2021 Issue
The Plague Year
The mistakes and the struggles behind America’s coronavirus tragedy.
By Lawrence Wright
December 28, 2020

New York Times
http://www.nytimes.com/
Accessed 9 Jan 2021
Europe
Pope Calls Coronavirus Vaccinations an Ethical Obligation
Saying he will be vaccinated himself next week, Francis described the refusal to get the vaccine as suicidal.
By Jason Horowitz

Health
Pressure Grows for States to Open Vaccines to More Groups of People
Some states are already expanding eligibility to people 65 and over, even though millions of people the C.D.C. recommends go first — health care workers and nursing home residents — have yet to get shots.
By Abby Goodnough

Europe
In Vaccine Geopolitics, a Great Game Played With Ukrainians’ Health
Blocked from obtaining vaccines from the United States, its putative ally, and taunted in Russian propaganda, Ukraine turned to China.
By Maria Varenikova

Politics
Biden Plans Coronavirus Vaccination Blitz After Inauguration
The incoming Biden administration plans to set up federally run mass vaccination sites and to release all government-held vials, rather than hold some back for second doses.
By Sheryl Gay Stolberg and Katherine J. Wu

Washington Post
https://www.washingtonpost.com/
Accessed 9 Jan 2021
Releasing more vaccines for first doses could create more problems than it solves
Leana S. Wen · Opinions · Jan 9, 2021

Tales from the jab: How people in 6 countries got their vaccines
Brian Murphy, Steve Hendrix, Emily Rauhala, Carrie Donovan, Robyn Dixon and Yvonne Gordon
Jan 9, 2021

French vaccine rollout slowed by red tape, focus on elderly
Jan 9, 2021

WHO: Rich nations, vaccine firms should stop bilateral deals
Jan 8, 2021

Iran’s top leader bans corona vaccines from US, Britain
Jan 8, 2021

Mexico to vaccinate rural elderly, but still awaits vaccine
Jan 5, 2021

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 9 Jan 2021
Op-Ed
Globalizing the COVID vaccine
Ngozi Okonjo-Iweala
Friday, January 8, 2021
 
 
Center for Global Development [to 9 Jan 2021]
http://www.cgdev.org/page/press-center
January 4, 2021
G7: Make Plans to Share Excess Vaccine Now
The reality is that getting back to normal means rapid vaccination of the entire world – to minimize further virus mutations, to enable regular trade and commerce, and to protect those that are unable to be vaccinated for other health reasons.
Amanda Glassman
 
 
Chatham House [to 9 Jan 2021]
https://www.chathamhouse.org/
Accessed 9 Jan 2021
[No new relevant content]

 
 
CSIS
https://www.csis.org/
Accessed 9 Jan 2021
[No new relevant content]

Council on Foreign Relations
http://www.cfr.org/
Accessed 9 Jan 2021
Coronavirus
Vaccine Diplomacy: China and SinoPharm in Africa
January 6, 2021
On December 3, John Nkengasong, director, Africa Centers for Disease Control and Prevention (Africa CDC), announced a 60 percent vaccination target—one estimate of the level needed to achieve herd immunity from COVID-19—in Africa’s fifty-four countries.

 
 
Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 9 Jan 2021
[No new relevant content]